El Instituto de Salud Carlos III utiliza cookies propias y de terceros para el correcto funcionamiento y visualización del sitio web por parte del usuario, así como la recogida de estadísticas. Si continúa navegando, consideramos que acepta su uso. Para más información visite nuestra Política de Cookies.
Ver más información

We protect your health through science

Search Bar

Usa comillas para buscar una secuencia de palabras exacta. Ej: "Proyectos Financiados"

Investigation

Arbovirus and imported viral diseases

Research Lines

Content with Investigacion Neumococos .

Neumococos

Vigilancia epidemiológica de los serotipos y genotipos que causan enfermedad neumocócica invasiva (ENI) en España. Caracterización molecular de factores de virulencia de neumococo. Identificación y caracterización de proteínas de neumococo candidatas a vacuna. Evaluación de mecanismos de evasión de la respuesta inmune en Streptococcus pneumoniae. Impacto de los biofilms bacterianos en la persistencia del tracto respiratorio. Mecanismos de cronicidad de aislados clínicos de neumococo en pacientes con enfermedad pulmonar obstructiva crónica.

Research projects

Content with Investigacion Neumococos .

1: Título del proyecto: Desarrollo de enzibióticos para combatir infecciones en pacientes con fibrosis quística provocadas por los patógenos Pseudomonas aeruginosa y Staphylococcus aureus: CF-TREAT

Referencia: CPP2022-009574 / MPY 375/23

Agencia Financiadora: Agencia Estatal de Investigación. MICINN.

Fecha Inicio:    01/12/2023
Fecha Fin:    30/11/2026
Financiación: 238.938 Euros
Investigadores principales: Roberto Díez Martínez, José E. Yuste Lobo y Pilar García Suárez

 

2: Título del proyecto: Desarrollo de enzibióticos para combatir infecciones humanas producidas por Enterococcus faecium resistente a vancomicina (ANTI‐VRE).
Proyecto CPP2021-009054 financiado por MICIU/AEI /10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR

Investigadores principales: Roberto Díez Martínez, Jose Yuste Lobo y Mirian Domenech

Periodo: 18/11/2022 - 17/11/2025

Cuantía total: 231.455 €

3: Título del proyecto: Mecanismos de virulencia en patógenos respiratorios.
Entidad financiadora: Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación (Convocatoria «Proyectos I+D+I» 2020 - Modalidades «Retos Investigación» y «Generación de Conocimiento»). Referencia: PID2020-119298RB-I00

Investigador principal: Jose Yuste Lobo

Periodo: 01/09/2021 - 30/08/2024

Cuantía total: 121.000 €

4: Título del proyecto: Efectividad de la vacuna antineumocócica conjugada 13-valente frente a la hospitalización por neumonía adquirida en la comunidad en adultos de 60 años o mayores, mediante un estudio de casos y controles modificado. Estudio CIBELES.

Investigadores principales: Jose Yuste Lobo y Ángel Gil de Miguel
Entidad financiadora: PFIZER. Referencia: MVP 249/20
Periodo: 23/02/2021 - 22/02/2025
Cuantía total: 168.000 €

5: Título del proyecto: Evolution of Invasive Pneumococcal Disease in Spain with special focus on the pathogenesis of serotypes 3, 8, 11A, 19A, 22F and 33F. Investigadores principales: Jose Yuste Lobo y Mirian Domenech.
Entidad financiadora: Merck Sharp & Dohme USA. Referencia: MVP 132/21
Período: 16/06/2021 - 15/12/2023
Cuantía total: 157.448€

6: Título del proyecto: Mecanismos de patogenicidad y protección en bacterias Gram-positivas causantes de enfermedad respiratoria y bacteriemia
Investigador principal: Jose Yuste Lobo
Entidad financiadora: MINECO. Referencia: SAF2017-83388-R
Periodo: 31/12/2017 - 30/06/2021
Cuantía total: 145.200 €

7: Título del proyecto: Characterization of susceptibility to cefditoren investigating penicillin resistant clinical isolates of Streptococcus pneumoniae.
Investigadores: Jose Yuste Lobo y Mirian Domenech Lucas
Entidad financiadora: Tedec Meiji Farma, S.A. Referencia: MVP 119/20
Periodo: 11/07/2020 – 10-07-2022
Cuantía total: 76.517 €

8: Título del proyecto: Impact of clinical isolates of serotypes 22F and 33F in the epidemiology and pathogenesis of Streptococcus pneumoniae.
Investigador principal: Jose Yuste Lobo
Entidad financiadora: Merck Sharp & Dohme España, S.A. Referencia: MVE 213/18
Periodo: 10/05/2018 - 30/05/2021
Cuantía total: 157.604 €

Search Bar

Publications

Sort
Category

Antitubercular drugs for an old target: GSK693 as a promising inhA direct inhibitor.

5. Martinez-Hoyos M, Perez-Herran E, Gulten G, Encinas L, Alvarez-Gomez D, Alvarez E, Ferrer Bazaga S, Garcia-Perez A, Ortega F, Angulo-Bartures I, Rullas-Trincado J, Blanco Ruano D, Torres P, Castañeda P, Huss S, Fernandez R, Gonzalez del Valle S, Ballel L, Barros D, Modha S, Dhar N, Signorino-Gelo F, McKinney JD, Garcia-Bustos JF, Lavandera JL, Sacchettini JC, Jimenez MS, Martin-Casabona N, Castro-PIchel J, Mendoza-Losana A. Antitubercular drugs for an old target: GSK693 as a promising inhA direct inhibitor. EBioMedicine. 2016; 8:291-301

PUBMED DOI

Peritoneal tuberculosis due to Mycobacterium caprae.

6. Nebreda T, Alvarez-Prida E, Blanco B, Remacha MS, Samper S, Jimenez MS. Peritoneal tuberculosis due to Mycobacterium caprae. ID Cases 2016; 4:50-52.

PUBMED DOI

Pediatric drug-resistant tuberculosis in Madrid family matters

7. Santiago B, Baquero-Artiago F, Mejias A, Blázquez D, Jimenez MS, Mellado-Peña MJ, EREMITA Study group. Pediatric drug-resistant tuberculosis in Madrid: family matters. The Pediatric Infectious Disease Journal. 2014; 33:345-350.

PUBMED DOI

Mycobacterium kumamotonense, another Member of the Mycobacterium terrae Complex Unusually Carrying Two Copies of the Ribosomal RNA Operon

8. Menéndez MC, Jiménez MS, Yubero J, García MJ. Mycobacterium kumamotonense, another Member of the Mycobacterium terrae Complex Unusually Carrying Two Copies of the Ribosomal RNA Operon. Mycobac Dis; 2014; 4:176.

DOI

Content with Investigacion Neumococos .

List of staff

Additional Information

Our objectives are research into well-established autochthonous viruses (Toscana, West Nile and Lymphocoriomeningitis), imported viruses with a vector in Spain (mainly Zika, Dengue and Chikungunya), and viruses that cause haemorrhagic fevers (such as Ebola, Lassa or Crimea Congo, which despite being autochthonous, we include in this category) without forgetting other viruses that, at any time, may become emerging viruses and cause public health alerts.

The group's main research objective is to identify and characterise the aforementioned viruses that cause disease and those circulating in our environment with pathogenic potential.

One of the cross-cutting objectives of the laboratory is to optimise methods for the detection of these viruses and their application to determine the incidence, prevalence and/or presence of the viruses in our environment.

However, in addition to methodological development, it is important to know the origin of the circulating viruses, their antigenic relationships with related viruses, the pathogenicity of the different isolates or the interactions of the agents with their host both in cell culture and in arthropod vectors when this is possible. The aim is to strengthen our role as a National Reference Laboratory for zoonoses through research.

Our objectives are research into well-established autochthonous viruses (Toscana, West Nile and Lymphocoriomeningitis), imported viruses with a vector in Spain (mainly Zika, Dengue and Chikungunya), and viruses that cause haemorrhagic fevers (such as Ebola, Lassa or Crimea Congo, which despite being autochthonous, we include in this category) without forgetting other viruses that, at any time, may become emerging viruses and cause public health alerts.

The group's main research objective is to identify and characterise the aforementioned viruses that cause disease and those circulating in our environment with pathogenic potential.

One of the cross-cutting objectives of the laboratory is to optimise methods for the detection of these viruses and their application to determine the incidence, prevalence and/or presence of the viruses in our environment.

However, in addition to methodological development, it is important to know the origin of the circulating viruses, their antigenic relationships with related viruses, the pathogenicity of the different isolates or the interactions of the agents with their host both in cell culture and in arthropod vectors when this is possible. The aim is to strengthen our role as a National Reference Laboratory for zoonoses through research.

Content with Investigacion Unidad de Investigación en Modelos y Mecanismos .